Three-year increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle-aged men and women: the D.E.S.I.R. cohort
Among hepatic markers, gamma-glutamyltransferase (GGT) is the main predictor for development of type 2 diabetes, but there are no data to date on changes in GGT and type 2 diabetes incidence.
Data at baseline and at 3 years from the D.E.S.I.R. cohort were used, comprising 2,071 men and 2,130 women without baseline diabetes.
Changes in GGT level were correlated with changes in markers of insulin resistance (fasting insulin, homeostasis model assessment of insulin resistance), as well as with the following elements of the metabolic syndrome: central obesity, and increased fasting glucose, triglycerides and blood pressure (systolic and diastolic). The 3-year increase in GGT was associated with incident type 2 diabetes in both sexes, after adjusting for age and baseline GGT. After further adjustment for baseline confounding factors, including alanine-aminotransferase, alcohol intake, obesity and fasting insulin, the odds ratios (95% CI) for an association between incident type 2 diabetes and unchanged or increased (as opposed to decreased) GGT levels were 2.54 (1.38–4.68) in men (p=0.003) and 2.78 (1.20–6.42) in women (p=0.02). These associations were slightly attenuated after adjusting for the 3-year change in BMI, alcohol consumption and fasting insulin, the odds ratios being 2.49 (1.28–4.86) in men and 2.53 (1.01–6.40) in women. This relationship was not dependent on intra-individual variability.
An unchanged or increased GGT level over time, even when GGT is in the normal range, is correlated with increasing insulin resistance and is associated with a risk of incident type 2 diabetes in both sexes, independently of baseline GGT, which is itself a diabetes risk factor.
- Perry IJ, Wannamethee SG, Shaper AG (1998) Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care 21:732–737
- Lee DH, Ha MH, Kim JH et al (2003) Gamma-glutamyltransferase and diabetes—a 4-year follow-up study. Diabetologia 46:359–364 CrossRef
- Nakanishi N, Nishina K, Li W, Sato M, Suzuki K, Tatara K (2003) Serum gamma-glutamyltransferase and development of impaired fasting glucose or type 2 diabetes in middle-aged Japanese men. J Intern Med 254:287–295 CrossRef
- Lee DH, Jacobs DR Jr, Gross M et al (2003) Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem 49:1358–1366 CrossRef
- Nakanishi N, Suzuki K, Tatara K (2004) Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 6:1427–1432
- Sattar N, Scherbakova O, Ford I et al (2004) Elevated alanine-aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 53:2855–2860
- Andre P, Balkau B, Born C et al (2005) Hepatic markers and development of Type 2 Diabetes, in middle aged men and women: a three-year follow-up study. Diabetes Metab 31:542–550
- Nilssen O, Forde OH (1994) Seven-year longitudinal population study of change in gamma-glutamyltransferase: the Tromso Study. Am J Epidemiol 139:787–792
- Sebastian-Gambaro MA, Liron-Hernandez FJ, Fuentes-Arderiu X (1997) Intra- and inter-individual biological variability data bank. Eur J Clin Chem Biochem 35:845–852
- Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modelling. Diabetes Care 27:1487–1495
- Three-year increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle-aged men and women: the D.E.S.I.R. cohort
Volume 49, Issue 11 , pp 2599-2603
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Insulin resistance
- Type 2 diabetes
- Industry Sectors